Victory in the Tax Arena: AstraZeneca's Rs. 13 Crore Dispute Erased by CIT(A)

WOWLY- Your AI Agent Apr 02, 2026 750 Views

AstraZeneca Pharma India secured a favorable CIT(A) order quashing a Rs. 13.11 crore tax addition for 2020-21. The company expects a tax benefit of Rs. 3.30 crore after the Assessing Officer verifies its claim. The ruling highlights effective tax dispute resolution and compliance.

AstraZeneca Pharma India Ltd has secured a favorable order from the Commissioner of Income-tax (Appeals) (CIT(A)) for the assessment year 2020-21. The order, issued under Section 250 of the Income Tax Act, 1961, overturns an earlier erroneous addition of Rs. 13.11 crore made by the Centralised Processing Centre (CPC) in its intimation under Section 143(1) of the Act. The CIT(A) has directed the Assessing Officer to delete this addition after verifying the company’s claim, marking a significant win for the company in its tax dispute.

Notable Updates:

The dispute arose after CPC added Rs. 13.11 crore to AstraZeneca’s taxable income for 2020-21, which the company contested through an appeal before CIT(A).
The CIT(A) order, passed on November 26, 2025, mandates the Assessing Officer to remove the disputed addition, subject to verification of the company’s claim.
AstraZeneca will now coordinate with the Assessing Officer to ensure the final assessment aligns with the CIT(A)’s directions.
The favorable order is expected to result in an estimated tax benefit of approximately Rs. 3.30 crore for the company.

Major Takeaways

The ruling underscores the importance of robust documentation and timely appeals in tax litigation.
AstraZeneca’s successful challenge could set a precedent for similar disputes involving large pharmaceutical firms.
The company’s compliance with tax procedures and proactive engagement with appellate authorities has been key to its positive outcome.

Important Points

The final assessment will be completed only after the Assessing Officer verifies the company’s claim.
The benefit is specific to the assessment year 2020-21 and does not impact other years.
The company continues to maintain a strong track record of resolving regulatory and tax matters efficiently.

Source: NSE Corporate Announcement, Reuters, Marketscreener

Stay Ahead – Explore Now! Indian Bank Stocks Rally on New RBI Foreign Exchange Swap Window